To demonstrate this hypothesis, in the present study, we compared the therapeutic efficacy between chemotherapy and first‐ or second‐generation EGFR TKIs as the second‐line treatment in EGFR‐mutated non‐small cell lung cancer (NSCLC) patients with T790M‐negative or unknown mutation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.